Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was just having some fun. Your right though, back to dd. did you buy more this morning? Got your .50's again.
I'm pretty sure that would be tax deductible. Even the IRS would admit that donating a friend to jumpingjacks would be charity.
Fellows: we will all have to donate a large amount. It's going to be hard to find a friend for jumpingjacks.
Go ahead and trade. I just don't understand your posts. Of course it is a trading stock when there is no significant news that moves the pps to the next level. Until then, the longs wait. Biotech 101.
I just don't get why you keep posting stock language from the 10q, etc. with warnings in them to be careful and reminding us that oncs doesn't have a product in the market. I think we all know this, even jumpingjacks and tvigit. I don't get it.
Sounds like it was more than just one anti- pd-1. Includes an anti ctla4 as well. Sound like 3 to 4 different combinations.
Maybe, maybe not. However, the proven positive catalyst is when you stop talking. Never fails.
Why are you copying and pasting the entire prospectus?
Absolutely!!! I was in cprx at .43 and sold at .72 only to watch it go to $3.52 a month later. Not this time.
What I mean by do both is by half today so you don't get caught with your pants down potentially Monday and if there is no PR, then buy more on the next dip.
Do both.
From the Yahoo Board:
IR Response to my Question:
"Thank you for reaching out, we sincerely appreciate your interest and support in the company. As discussions with the FDA are ongoing and confidential in nature, it is not our policy to disclose specific details. Thanks again for getting in touch, we look forward to addressing any future inquiries in a timely and efficient manner. Have a great weekend!"
Well, at least we know the FDA discussions are happening as we speak.
I hope everyone who can is taking advantage if this.
Welcome back.
That's your first comment EVER that could be construed as you actually owning shares. WELL DONE!!!!!!
Really, you guys have got to listen to this. I'm so glad we have Dr. Pierce.
If you all want to be inspired, listen to Roger Perlmutter (CEO at Merck), discuss immuno-oncology at the the Goldman Sacks HealthCare Conference on 6/12/2014!!! Start listening at minute 18:00. He outlines their criteria for choosing partners.
He says the key question is turning non-responders to responders. Further, he emphasizes the immuno-suppressant environment is the key factor. Almost word for word what Pierce was describing in the mouse studies.
Also, he compares the other PD-1's of their competitors.
Take a listen and be inspired.
http://cc.talkpoint.com/gold006/061014a_an/?entity=107_731DYU0
I was wondering if the science gurus would comment on the attached link. This is Merck's ASCO presentation. Go to the bottom and click the "ASCO Event" link. I was wondering if there were some nuances that we could gather from Merck's summary that would fall in line with ONCS' plan.
http://www.merck.com/investors/home.html
This was their case description:
Inovio Pharmaceuticals (NYSE: INO) engaged AMP in July of 2012; traded on the NYSE Markets. In July of 2012 the stock was traded at .45 cents with roughly 240,000 shares of daily volume. We have increased retail participation and made introductions into multiple broker-dealers. We have introduced the company to over 5000 Registered Financial advisors/Stock Brokers/Small Funds or Institutions. The stock has traded as high as $3.95 a share on February 24, 2014. The stock is currently trading around $3.75 a share with average volume of 7.2 million shares a day. We have very high expectations for this company over the next 12 months. INO has also just recommitted to another one year contract with AMP.
Yup. And, when one institution commits, the next one for easily follows.
Accorn's clients seem to be half biotechnology and half energy based which is an interesting mix.
I like the line that INO decided to re-new their contract with Accorn. Obviously, they were happy with the service they received.
The timing of them hiring Acorn definitely corresponds to the private placement. Hopefully, more institutional investment to come.
This is interesting behind the scenes work that ONCS has been doing. they hired Acorn managements, LLC in Feb 2014 to increase their awareness in the financial community.
http://www.acornmanagementpartners.com/case-studies
This is from March but is pretty good. It is an analysis from Acorn Management Partners, LLC.
http://content.stockpr.com/acornmanagementpartners/db/Client+Documents/5324/file/ONCS+CP.PDF
That's what I would do, just sayin. :)
Maybe he is bored in the meeting. I'm bored in meetings all the time. Half of my posts are from when I'm bored and in court.
In a research note issued this morning, H.C. Wainwright analyst Reni Benjamin reiterated coverage with a “Buy” rating on OncoSec Medical Inc. (ONCS), and a price target of $2.00 a share based on a comparables analysis of similarly staged biotechnology companies with platform technologies.
“With multiple upcoming presentations, the potential for a partnership, and a strong cash position of approximately $39 MM (pro forma), we believe OncoSec represents an undervalued player with significant upside for the long-term investor”, wrote Benjamin.
https://www.tipranks.com/experts/reni-benjamin
Also, I kind of feel that from Punit's perspective, the more time oncs gets to develop its pipeline alone, the higher the partnership price goes. They sound like they are doing some amazing things in Seattle.
The numbers that I feel are realistic are 100-120 million up front with payments to 500 million.
Jumpingjackass: feel free to post another worthless, critical comment.
I think that oncs will get more than even this deal.
http://mobile.reuters.com/article/idUSKBN0ET0OO20140618?irpc=932
I agree. After today's volume, pretty likely.
Six more left.
Lol, True, true. Glad you are out of complaining mode and back to yourself.
To give him credit, he is more creative that tvgit who is on auto response.
Jumpinjackas hopefully has only 7 more insulting posts left. Countdown.
Thanks man. Hope that circles around.
Post the link canoe.
I don't really disagree with anything you have said.
Absolutely. Go ahead.
All of you who care about this company, its important to send encouraging tweets and/or e-mails to Punit and ONCS. They are people too and are doing a great job. Just watch. We are in something really special. Not only great science but a great management team. They should know positive feedback from their investors in addition to negative.
Of course I read into everything. That's why its interesting!!!! :) But, I don't share your concerns about his tweeting.
Honestly, Punit so far has hit it out of the park as far as running this company. Even with the S-3 filing (especially if there is a partnership announced soon), I believe he and his team have made solid decision after solid decision. That is is why the company is positioned so well right now. We are very fortunate.
No tweets today guys. Maybe he is signing the partnership agreement or meeting with the FDA. :)
Trading Jeff: I really don't think we should tell Punit anything about how much he tweets. That's totally his call.
Guys: What we really need to do is gather questions to ask Punit in our quarterly Q & A that Zoridan has agreed to conduct.
Pretty steady and consistent buying. Looking good.
No kidding. I'm actually getting kind of sick of it. As I've said before, the fundamentals of this stock are really, really good, including the finances.
These same complaints about Punit's tweet with be turned into lover letters as soon as this turns around.